Alendronate treatment in the revision setting, with and without controlled implant motion

References

• Aspenberg P, Herbertsson P. Periprosthetic bone resorption. Particles vs. movement. J Bone Joint Surg (Br) 1996; 78(4)641–6
   PubMedGoogle Scholar
• Aspenberg P, Van der Vis H. Migration, particles and fluid pressure A discussion of causes of prosthetic loosening. Clin Orthop 1998; 352: 75–80
   Google Scholar
• Aspenberg P, Goodman S, Toksvig-Larson S, Ryd L, Albrektsson T. Intermittent micromotion inhibits bone ingrowth. Titanium implants in rabbits. Acta Orthop Scand 1992; 63(2)141–5
   PubMed Web of Science ®Google Scholar
• Astrand J, Aspenberg P. Alendronate did not inhibit instability-induced bone resorption A study in rats. Acta Orthop Scand 1999; 70(1)67–70
   PubMed Web of Science ®Google Scholar
• Astrand J, Aspenberg P. Reduction of instability-induced bone resorption using bisphosphonates High doses are needed in rats. Acta Orthop Scand 2002; 73(1)24–30
   PubMed Web of Science ®Google Scholar
• Astrand J, Skripitz R, Skoglund B, Aspenberg P. A rat model for testing pharmacologic treatment of pressure-related bone loss. Clin Orthop 2003; 409: 296–305
   Google Scholar
• Astrand J, Aspenberg P. Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening. J Orthop Res 2004; 22(2)244–9
   PubMedGoogle Scholar
• Bauer D C, Garnero P, Hochberg M C, Santora A, Delmas P, Ewing S K, Black D M. for the Fracture Intervention Research Group Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006; 21(2)292–9
   PubMedGoogle Scholar
• Bechtold J E, Soballe K, Kubic V, Gustilo R. A controlled experimental model of revision implants Part I. Acta Orthop Scand 2001a; 72(6)642–9
   PubMed Web of Science ®Google Scholar
• Bechtold J E, Mouzin O, Kidder L, Soballe K. A controlled experimental model of revision implants Part II. Acta Orthop Scand 2001b; 72(6)650–6
   PubMed Web of Science ®Google Scholar
• Bechtold J E, Soballe K, Overgaard S, Kubic V, Lewis J. Bone ingrowth in the presence of particulate polyethylene, synergy between interface motion and periprosthetic tissue response. J Bone Joint Surg (Br) 2002; 84(6)915
   PubMedGoogle Scholar
• Bhandari M, Bajammal S, Guyatt G H, Griffith L, Busse J W, Schunemann H, Einhorn T A. Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty. A meta-analysis J Bone Joint Surg (Am) 2005; 87(2)293–301
   PubMed Web of Science ®Google Scholar
• Black D M, Thompson D E, Bauer D C, Ensrud K, Musliner T, Hochberg M C, Nevitt M C, Surywanshi S, Cummings S R. The FIT Research Group Fracture Intervention Trial. The FIT Research Group Fracture risk reduction with alendronate in women with ostheoporosis: the fracture intervention trial. J Clin Endocrinol Metab 2000; 85(11)4118–24, Erratum in J Clin Endocrinol Metab 2001; 86 2 938
   PubMed Web of Science ®Google Scholar
• Cecchini M G, Felix R, Fleisch H, Cooper P H. Effect of bisphosphonates on proliferation and viability of mouse bone marrow ferived macrophages. J Bone Miner Res 1987; 2(2)135–42
   PubMedGoogle Scholar
• Chappard D, Petitjean M, Alexandre C, Vico L, Minaire P, Riffat G. Cortical osteoclasts are less sensitive to etidronate than trabecular osteoclasts. J Bone Miner Res 1991; 7: 673–80
   Google Scholar
• Dohmae Y, Bechtold J E, Sherman R E, Puno R M, Gustilo R B. Reduction in cement-bone interface shear strength between primary and revision arthroplasty. Clin Orthop 1988; 236: 214–20
   Google Scholar
• Eberhardt C, Schwarz M, Kurth A H. High dosage treatment of nitrogen-containing bisphosphonate ibandronate is required for osseointegration of cementless metal implants. J Orthop Sci 2005; 10(6)622–6
   PubMedGoogle Scholar
• Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4(1)30–4
   PubMed Web of Science ®Google Scholar
• Garcia-Moreno C, Serrano S, Nacher M, Farre M, Diez A, Marinoso M L, Carbonell J, Mellibovsky L, Nogues X, Ballester J, Aubia J. Effect of alendronate on cultured normal human osteoblasts. Bone 1998; 22: 233–9
   PubMed Web of Science ®Google Scholar
• Hu J H, Ding Ming, Soballe K, Bechtold J E, Danielson C C, Day J S, Hvid I. Effects of short-term alendronate treatment on the three-fimensional microstructural, physical and mechanical properties of dog trabecular bone. Bone 2002; 31(5)591–7
   PubMedGoogle Scholar
• Jensen T B, Bechtold J E, Chen X, Soballe K. Systemic alendronate treatment improves fixation of press-fit implants. A canine study using non-loaded implants. J Orthop Res 2007; 22, [Epub ahead of print] PMID: 17318896
   Google Scholar
• Jeppsson C, Astrand J, Tagil M, Aspenberg P. A combination of bisphosphonate and BMP additives in impacted bone allografts. Acta Orthop Scand 2003; 74(4)483–9
   PubMed Web of Science ®Google Scholar
• Kold S, Bechtold J E, Mouzin O, Elmengaard B, Chen X, Soballe K. Fixation of revision implants is improved by a surgical technique to crack the sclerotic bone rim. Clin Orthop 2005, 432160-6
   Google Scholar
• Michael W R, King W R, Wakim J M. Metabolism of disodium ethane-1-hydroxy-1, 1-diphosphinate (disodium etidronate) in the rat, rabbit, dog and monkey. Toxicol Appl Pharmacol 1972; 21: 503–15
   PubMed Web of Science ®Google Scholar
• Millett P J, Allen M J, Bostrom M P. Effects of alendronate on particle-induced osteolysis in a rat model. J Bone Joint Surg (Am) 2002; 84: 236–49
   PubMed Web of Science ®Google Scholar
• Mochida Y, Bauer T W, Akisue T, Brown P R. Alendronate does not inhibit early bone apposition to hydroxyapatitecoated total joint implants A preliminary study. J Bone Joint Surg (Am) 2002; 84: 226–35
   PubMedGoogle Scholar
• Mouzin O, Bechtold J E, Søballe K. Loading improves anchorage of hydroxyapatite implant more than titanium implants. J Biomed Mat Res 2001; 58(1)61–8
   PubMed Web of Science ®Google Scholar
• Rodan G A. Bone mass homeostasis and bisphosphonate action. Bone 1997; 20(1)1–4
   PubMedGoogle Scholar
• Shanbhag A S, Hasselman C T, Rubash H E. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop 1997; 344: 33–43
   PubMed Web of Science ®Google Scholar
• Soballe K, Hansen E S, B-Rasmussen H, Bunger C. Tissueingrowth into titanium and hydroxyapatite coated implants during stable and unstable mechanical conditions. J Orthop Res 1992; 10: 285–99
   PubMed Web of Science ®Google Scholar
• Soballe K, B-Rasmussen H, Hansen E S, Bunger C. Hydroxyapatite coating converts fibrous tissue to bone around loaded implants. J Bone Joint Surg (Br) 1993; 75(2)270–8
   PubMedGoogle Scholar
• Soballe K, Mouzin O, Kidder L, Overgaard S, Bechtold J E. The effects of hydroxyapatite coating and bone allograft on fixation of loaded experimental primary and revision implants. Acta Orthop Scand 2003; 74(3)239–47
   PubMedGoogle Scholar
• Soballe K, Jensen T B, Mouzin O, Kidder L, Bechtold J E. Differential effect of a bone morphogenetic protein-7 (OP-1) on primary and revision loaded, stable implants with allograft. J Biomed Mater Res A. 2004; 15(71)4, 569–76
   Google Scholar
• Tucci J R, Tonino R P, Emkey R D, Peverly C A, Kher U, Santora A C. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996; 101(5)488–501
   PubMed Web of Science ®Google Scholar
• Vestermark Toft M, Bechtold J E, Swider P, Soballe K. Mechanical interface conditions affect morphology and cellular activity of sclerotic bone rims forming around experimental loaded implants. J Orthop Res 2004; 22(3)647–52
   PubMedGoogle Scholar
• Wise L M, Waldman S D, Kasra M, Cheung R, Binnington A, Kandel R A, White L M, Grynpas M D. Effect of zoledronate on bone quality in the treatment of aseptic loosening of hip arthroplasty in the dog. Calcif Tissue Int 2005; 77(6)367–75
   PubMed Web of Science ®Google Scholar